TopoTarget

TopoTarget was a Copenhagen-based biotechnology company established in 2000 by clinicians working on the molecular biology of cancer. The company concentrated on discovering and advancing medicines aimed at defined biological mechanisms, particularly histone deacetylase inhibition, apoptosis, topoisomerase activity, and other pathways associated with tumor growth and survival. Rather than operating solely as an internal drug-discovery laboratory, TopoTarget built its portfolio through a combination of proprietary research, acquisitions, licensing transactions, and collaborations with academic institutions, hospitals, government research bodies, and pharmaceutical companies. The company expanded rapidly during the first decade of its existence. It acquired Prolifix in the United Kingdom in 2002, G2M Cancer Drugs in Germany in 2005, and Apoxis in 2007. These transactions added research programs and development assets, including APO010 and APO866. TopoTarget also maintained scientific and commercial relationships with organizations such as the United States National Cancer Institute, the Netherlands Cancer Institute, Rigshospitalet in Copenhagen, Novartis, Lundbeck, Astellas, LEO Pharma, and CuraGen. Its stated business model combined in-licensing of early-stage compounds with out-licensing or partnering of assets that required larger-scale late-stage development, regulatory work, and commercialization. TopoTarget's most visible commercial product during its independent period was Savene, also marketed in the United States as Totect. The dexrazoxane-based medicine was developed for anthracycline extravasation, a rare but serious complication in which chemotherapy leaks from a blood vessel into surrounding tissue. European authorization was obtained in 2007, followed by United States availability later that year. The product gave the company its first marketed medicine and contributed to a substantial increase in reported revenue during the mid-2000s. Its leading oncology development program was belinostat, also known as PXD101, a histone deacetylase inhibitor. TopoTarget developed the compound with research and clinical support involving the National Cancer Institute. Belinostat was studied in hematological malignancies and solid tumors, including peripheral T-cell lymphoma, and received orphan-drug and fast-track designations from the United States Food and Drug Administration. It was subsequently approved in the United States under the brand name Beleodaq for relapsed or refractory peripheral T-cell lymphoma. Other programs included Savicol for familial adenomatous polyposis, Baceca and Avugane topical valproic-acid formulations, TopotectA for brain metastases, Zemab, APO010, APO866, APO200, and preclinical heat-shock-protein-90 inhibitors. TopoTarget was publicly traded in Copenhagen under the symbol TOPO and operated across Denmark, Germany, Switzerland, the United Kingdom, and the United States. In 2014, it merged with the French biotechnology company BioAlliance Pharma. The combined company became Onxeo, and TopoTarget ceased to exist as an independent corporate entity. Accordingly, TopoTarget is best understood today as a former Danish oncology biotechnology company whose principal legacy is its contribution to the development and commercialization of belinostat and Savene/Totect.

TopoTarget was founded in 2000 in Denmark by clinicians interested in translating knowledge of cancer biology into medicines. Its early research and development model emphasized molecularly defined targets and collaboration. In 2001, the company began working with the United States National Cancer Institute on anticancer agents, a relationship that became particularly relevant to the development of belinostat. It also developed links with Rigshospitalet in Copenhagen and the Netherlands Cancer Institute, while later commercial and scientific relationships involved Novartis, Lundbeck, CuraGen, Astellas, and LEO Pharma. Acquisitions were a central part of TopoTarget's expansion. The company purchased Prolifix in 2002, G2M Cancer Drugs in 2005, and Apoxis in 2007. These deals broadened its research capabilities and added programs based on apoptosis, NAD biosynthesis, and other cancer-related mechanisms. By the middle of the 2000s, the business had assembled staff involved in assay development, medicinal chemistry, preclinical research, clinical trials, marketing, and sales across several countries. TopoTarget pursued a portfolio strategy that divided responsibilities between the company and external partners. It sought to license promising early-stage compounds, conduct initial research and development internally, and use larger pharmaceutical or institutional partners for later clinical, regulatory, or commercial activities. A 2004 agreement with CuraGen gave TopoTarget access to a group of histone deacetylase inhibitors, including belinostat. The company also obtained rights from Astellas to compounds with possible anticancer or immunosuppressive applications, acquired rights to a preclinical HDAC inhibitor from LEO Pharma, and obtained development rights to the sigma-receptor ligand siramesine from Lundbeck. Savene was the company's first marketed product. Based on dexrazoxane, it was developed to treat anthracycline extravasation, an uncommon chemotherapy complication involving leakage into tissue around an infusion site. European authorization was granted in 2007, and the product was subsequently marketed in the United States as Totect. The launch helped move TopoTarget from a development-stage biotechnology company toward a commercial oncology business. Belinostat became the company's principal development asset. The intravenous HDAC inhibitor was studied in hematological cancers and solid tumors, including peripheral T-cell lymphoma. Work with the National Cancer Institute supported clinical investigation of the drug both as a single agent and in combination regimens. Belinostat received United States orphan-drug and fast-track designations and was later approved as Beleodaq for relapsed or refractory peripheral T-cell lymphoma. The wider pipeline included Savicol, a valproic-acid formulation investigated for familial adenomatous polyposis; Baceca and Avugane, topical formulations intended for skin cancer, precancerous lesions, or inflammatory skin disease; TopotectA, a dexrazoxane-related program for brain metastases; Zemab, an ErbB2/HER2-directed antibody-toxin; APO010, a Fas-ligand-derived recombinant protein; APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis; APO200, a program for X-linked hypohidrotic ectodermal dysplasia; and preclinical HSP90 inhibitors. Several programs remained experimental, were discontinued, or were considered for partnering rather than commercialization. TopoTarget was listed on the OMX Nordic Exchange in Copenhagen under TOPO. The company ultimately merged with BioAlliance Pharma in 2014. The resulting business adopted the name Onxeo, ending TopoTarget's independent corporate existence. Its historical significance lies in the creation of a Danish oncology-focused biotechnology platform, the development of Savene/Totect, and the advancement of belinostat into an approved cancer medicine.

• 2014

  Merger with BioAlliance Pharma

  [1]TopoTargeten.wikipedia.org

  TopoTarget merged with BioAlliance Pharma, and the combined company became Onxeo.

• 2007

  Acquisition of Apoxis

  [1]TopoTargeten.wikipedia.org

  The Apoxis acquisition added development programs including APO010 and APO866.

• 2007

  Savene authorized in Europe

  [1]TopoTargeten.wikipedia.org

  The European Commission authorized Savene for anthracycline extravasation.

• 2005

  Acquisition of G2M Cancer Drugs

  [1]TopoTargeten.wikipedia.org

  TopoTarget acquired the German company G2M Cancer Drugs, continuing its acquisition-led portfolio expansion.

• 2002

  Acquisition of Prolifix

  [1]TopoTargeten.wikipedia.org

  The acquisition of the United Kingdom company Prolifix expanded TopoTarget's drug-discovery and development capabilities.

• 2001

  Collaboration with the National Cancer Institute begins

  [1]TopoTargeten.wikipedia.org

  TopoTarget began a research relationship with the United States National Cancer Institute focused on anticancer drug development.

• 2000

  TopoTarget founded

  [1]TopoTargeten.wikipedia.org

  Clinicians established TopoTarget in Denmark to discover and develop mechanism-based cancer therapies.

A specialist oncology biotechnology developer focused on mechanism-based cancer therapies and partnerships across the drug-development lifecycle.

• Histone deacetylase inhibitor

  Belinostat

  Belinostat, also known as PXD101, was TopoTarget's leading oncology development program. It is a histone deacetylase inhibitor investigated in hematological malignancies and solid tumors, including peripheral T-cell lymphoma. The compound received orphan-drug and fast-track designations in the United States and was later approved under the brand name Beleodaq for relapsed or refractory peripheral T-cell lymphoma.

• Oncology supportive-care medicine · 2007

  Savene

  Savene is a dexrazoxane-based medicine developed for anthracycline extravasation, in which anthracycline chemotherapy unintentionally leaks into surrounding tissue. It was supplied as a treatment kit containing powder and diluent. The product was authorized in Europe in 2007 and marketed in the United States as Totect.

• Cancer drug candidate

  Savicol

  Savicol, formerly called PEAC, was a proprietary formulation intended to deliver valproic acid through a controlled pharmacokinetic profile. TopoTarget investigated it as an HDAC-related treatment for colorectal polyps in patients with familial adenomatous polyposis. The program received orphan-drug designations in the United States and Europe and entered mid-stage clinical research.

• Small-molecule oncology candidate

  APO866

  APO866 was a potent inhibitor of nicotinamide phosphoribosyltransferase, an enzyme involved in the production of NAD. TopoTarget obtained worldwide development and marketing rights from Astellas and studied the compound in advanced melanoma, cutaneous T-cell lymphoma, and relapsed or refractory B-cell chronic lymphocytic leukemia. A cutaneous T-cell lymphoma study was later stopped for lack of efficacy.

• Recombinant protein oncology candidate

  APO010

  APO010, also known as mega-FasLigand, was a recombinant fusion protein derived from the pro-apoptotic human Fas ligand. The proposed mechanism was activation of Fas receptors on cancer cells, triggering programmed cell death. TopoTarget investigated it in an early clinical study involving patients with advanced or refractory solid tumors.

• Topoisomerase II inhibitor candidate

  TopotectA

  TopotectA was a dexrazoxane-related program investigated for brain metastases, including metastases associated with lung and breast cancers. It was linked to a research collaboration with Rigshospitalet and entered early clinical evaluation.

• Topical oncology candidate

  Baceca

  Baceca was a topical valproic-acid formulation intended for hyperproliferative skin conditions, including basal-cell carcinoma and actinic keratosis. Its proposed activity involved inhibition of class I histone deacetylases associated with cellular proliferation and tumorigenesis.

• Topical dermatology candidate

  Avugane

  Avugane was a topical formulation of valproic acid investigated primarily for inflammatory skin conditions such as acne. TopoTarget conducted randomized mid-stage studies and considered possible applications in disorders including psoriasis and atopic dermatitis.

• Antibody-toxin biologic candidate

  Zemab

  Zemab was a recombinant antibody-toxin designed to target the ErbB2/HER2 receptor, which is overexpressed in a subset of breast cancers and implicated in other malignancies. The program was intended to deliver a toxic payload selectively to receptor-bearing tumor cells, but later clinical-trial registration was not documented in the supplied material.

• Rare-disease recombinant protein candidate

  APO200

  APO200 was a recombinant protein program derived from the ectodysplasin A1 pathway and intended for X-linked hypohidrotic ectodermal dysplasia. Preclinical animal studies indicated potential activity, and the program received United States orphan-drug status. TopoTarget considered licensing or divesting the project rather than developing it as a core oncology asset.

• 2014

  Merger with BioAlliance PharmaM&A

  Background

  TopoTarget and BioAlliance Pharma combined their oncology-focused activities to create a larger specialized biotechnology company.

  Action taken

  The companies merged, and the resulting business adopted the name Onxeo.

  Aftermath

  TopoTarget ceased operating as an independent company and became part of Onxeo.

  Source

• 2007

  Acquisition of ApoxisM&A

  Background

  TopoTarget used acquisitions to add oncology programs and scientific capabilities beyond its original Danish operations.

  Action taken

  The company acquired Apoxis, bringing programs such as APO010 and APO866 into its portfolio.

  Aftermath

  The transaction broadened TopoTarget's clinical pipeline in recombinant proteins and small-molecule cancer therapeutics.

  Source

• 2004

  License and collaboration agreement with CuraGenStrategy

  Background

  TopoTarget sought to expand its oncology pipeline through external access to promising small molecules, particularly compounds affecting histone deacetylase enzymes.

  Action taken

  The company entered an agreement with CuraGen covering research, development, and commercialization of a group of HDAC-inhibiting small molecules, including belinostat.

  Aftermath

  Belinostat became TopoTarget's principal development asset and later reached approval in the United States as Beleodaq.

  Source

1. 1TopoTargeten.wikipedia.org